Microwave Ablation Combined With Neoadjuvant Chemotherapy and Immunotherapy in Resectable Stage IIB-IIIB Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.

IF 2.3 3区医学 Q3 ONCOLOGY

Thoracic Cancer Pub Date : 2025-08-01 DOI:10.1111/1759-7714.70136

Chun-Quan Liu, Kang-Shun Guo, Qi Qin, Liu Yang, Yong Cui, Mu Hu

{"title":"Microwave Ablation Combined With Neoadjuvant Chemotherapy and Immunotherapy in Resectable Stage IIB-IIIB Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.","authors":"Chun-Quan Liu, Kang-Shun Guo, Qi Qin, Liu Yang, Yong Cui, Mu Hu","doi":"10.1111/1759-7714.70136","DOIUrl":null,"url":null,"abstract":"Background: Chemotherapy combined with immunotherapy has emerged as a pivotal neoadjuvant strategy for resectable locally advanced non-small cell lung cancer (NSCLC). However, several problems urge to be resolved, including suboptimal pathologic complete response(pCR)/major pathologic response (MPR). Microwave ablation (MWA) exerts direct tumoricidal effects through thermal coagulation while releasing tumor-associated antigens to remodel the local immune microenvironment. In patients with advanced NSCLC, MWA combined with chemotherapy or immunotherapy has shown prolonged overall survival (OS).Methods: This study investigated the neoadjuvant therapeutic strategy combining MWA with chemotherapy and immunotherapy for optimizing neoadjuvant treatment strategies of stage IIB-IIIB NSCLC. We evaluated the pCR, MPR, R0 resection rate, and incidence of grade ≥ 3 adverse events in patients following surgical resection, aiming to improve surgical outcomes and survival.Results: This study confirmed the safety and feasibility of a neoadjuvant therapeutic strategy combining MWA with chemotherapy and immunotherapy in patients with NSCLC. The study was a single-center retrospective analysis (n = 8), demonstrating a pCR rate of 50%, an MPR rate of 62.5%, an R0 resection rate of 100%, with no increase in grade ≥ 3 adverse events.Conclusions: In this retrospective analysis, the neoadjuvant therapeutic strategy combining MWA with chemotherapy and immunotherapy preliminarily demonstrates safety and feasibility in resectable stage IIB-IIIB NSCLC, while showing potential to improve pCR and MPR rates. Furthermore, the integration of MWA may propose a novel treatment approach for optimizing neoadjuvant therapy. Prospective multicenter clinical trials are required to further validate the safety and feasibility, as well as its impact on long-term survival benefits.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 15","pages":"e70136"},"PeriodicalIF":2.3000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314312/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thoracic Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1759-7714.70136","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Chemotherapy combined with immunotherapy has emerged as a pivotal neoadjuvant strategy for resectable locally advanced non-small cell lung cancer (NSCLC). However, several problems urge to be resolved, including suboptimal pathologic complete response(pCR)/major pathologic response (MPR). Microwave ablation (MWA) exerts direct tumoricidal effects through thermal coagulation while releasing tumor-associated antigens to remodel the local immune microenvironment. In patients with advanced NSCLC, MWA combined with chemotherapy or immunotherapy has shown prolonged overall survival (OS).

Methods: This study investigated the neoadjuvant therapeutic strategy combining MWA with chemotherapy and immunotherapy for optimizing neoadjuvant treatment strategies of stage IIB-IIIB NSCLC. We evaluated the pCR, MPR, R0 resection rate, and incidence of grade ≥ 3 adverse events in patients following surgical resection, aiming to improve surgical outcomes and survival.

Results: This study confirmed the safety and feasibility of a neoadjuvant therapeutic strategy combining MWA with chemotherapy and immunotherapy in patients with NSCLC. The study was a single-center retrospective analysis (n = 8), demonstrating a pCR rate of 50%, an MPR rate of 62.5%, an R0 resection rate of 100%, with no increase in grade ≥ 3 adverse events.

Conclusions: In this retrospective analysis, the neoadjuvant therapeutic strategy combining MWA with chemotherapy and immunotherapy preliminarily demonstrates safety and feasibility in resectable stage IIB-IIIB NSCLC, while showing potential to improve pCR and MPR rates. Furthermore, the integration of MWA may propose a novel treatment approach for optimizing neoadjuvant therapy. Prospective multicenter clinical trials are required to further validate the safety and feasibility, as well as its impact on long-term survival benefits.

Abstract Image

查看原文本刊更多论文

微波消融联合新辅助化疗和免疫治疗可切除期IIB-IIIB非小细胞肺癌：一项单中心回顾性研究

背景：化疗联合免疫治疗已成为可切除的局部晚期非小细胞肺癌（NSCLC）的关键新辅助治疗策略。然而，有几个问题亟待解决，包括不理想的病理完全反应(pCR)/主要病理反应（MPR）。微波消融（MWA）通过热凝固发挥直接的杀瘤作用，同时释放肿瘤相关抗原，重塑局部免疫微环境。在晚期NSCLC患者中，MWA联合化疗或免疫治疗可延长总生存期（OS）。方法：本研究探讨MWA联合化疗和免疫治疗的新辅助治疗策略，以优化IIB-IIIB期NSCLC的新辅助治疗策略。我们评估了手术切除后患者的pCR、MPR、R0切除率和≥3级不良事件的发生率，旨在改善手术结果和生存率。结果：本研究证实了MWA联合化疗和免疫治疗对NSCLC患者的新辅助治疗策略的安全性和可行性。该研究为单中心回顾性分析（n = 8）， pCR率为50%，MPR率为62.5%，R0切除率为100%，≥3级不良事件无增加。结论：在本回顾性分析中，MWA联合化疗和免疫治疗的新辅助治疗策略在可切除的IIB-IIIB期NSCLC中初步显示出安全性和可行性，同时显示出提高pCR和MPR率的潜力。此外，MWA的整合可能为优化新辅助治疗提供一种新的治疗方法。需要前瞻性多中心临床试验来进一步验证安全性和可行性，以及其对长期生存益处的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Thoracic Cancer ONCOLOGY-RESPIRATORY SYSTEM

CiteScore

5.20

自引率

3.40%

发文量

439

审稿时长

2 months

期刊介绍： Thoracic Cancer aims to facilitate international collaboration and exchange of comprehensive and cutting-edge information on basic, translational, and applied clinical research in lung cancer, esophageal cancer, mediastinal cancer, breast cancer and other thoracic malignancies. Prevention, treatment and research relevant to Asia-Pacific is a focus area, but submissions from all regions are welcomed. The editors encourage contributions relevant to prevention, general thoracic surgery, medical oncology, radiology, radiation medicine, pathology, basic cancer research, as well as epidemiological and translational studies in thoracic cancer. Thoracic Cancer is the official publication of the Chinese Society of Lung Cancer, International Chinese Society of Thoracic Surgery and is endorsed by the Korean Association for the Study of Lung Cancer and the Hong Kong Cancer Therapy Society. The Journal publishes a range of article types including: Editorials, Invited Reviews, Mini Reviews, Original Articles, Clinical Guidelines, Technological Notes, Imaging in thoracic cancer, Meeting Reports, Case Reports, Letters to the Editor, Commentaries, and Brief Reports.